Private: Fullwidth Portfolio Post

20

May2021
ISPOR 2021 runs between May 17-20 with the theme of HEOR: Evolving for Tomorrow's Challenges. During the conference, PDCI Market Access will be presenting a poster titled: Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada on May 18th 2021 from 11:30:00 AM ... Read More

29

Mar2021
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CADTH reimbursement review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

08

Oct2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

07

Jul2020
PDCI Market Access Inc. is pleased to share its best practices infographic focused on Requesting Reconsideration under the Canadian Agency for Drugs and Technologies in Health (CADTH) Procedures for the Common Drug Review (CDR). While optional and only appropriate in select circumstances, manufacturers should not overlook this potential opportunity ... Read More

02

Jul2020
Request-for-Reconsideration-To-CADTHDownload

30

Jun2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH ... Read More

14

Feb2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website. In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More

13

Jan2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.  CADTH released new updates to economic Category 1 Requirements ... Read More

27

Nov2019
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. This CADTH update primarily ... Read More

07

Oct2019
In July 2019, CADTH announced a new round of public consultations on its Pharmaceutical Review Programs. CADTH’s proposed changes would affect how it manages, reviews and reconsiders information submitted by pharmaceutical manufacturers through its Common Drug Review. Stakeholders were invited to submit feedback on three consultations: Proposal to Enhance ... Read More